Today, Kazia Therapeutics Limited (NASDAQ: KZIA) is moving higher on the charts in premarket trades. The KZIA stock is up more than 11.69% to trade at $12.42 as of the last check. Kazia Therapeutics stock closed the weekend session at $11.12 down -1.33%.
During the past three months, the volume of KZIA shares traded was 153.95K, which was higher than the 0.13 million shares traded in the last session. The price of Kazia stock has been rising following news of a commercialization agreement for its lead product in greater China.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
- The Top Cryptocurrency Stocks Flight in the Market for long-term
- Top 3 Cybersecurity Stocks You Should Keep on your Watch List
What does the agreement cover?
Kazia Therapeutics Limited is an Australian-headquartered company that develops cancer treatments. Our leading program is paxalisib, a PI3K/Akt/mTOR inhibitor intended to treat glioblastoma, the most malignant primary brain cancer in adults. The clinical trial for paxalisib, a major advancement in the treatment of glioblastoma, began recruiting patients in January 2021.
Kazia Therapeutics today announced a licensing agreement with Simcere Pharmaceutical Group Ltd involving the development and commercialization of Kazia’s investigational new drug, paxalisib, in Greater China.
- Mainland China, Hong Kong, Macau, and Taiwan are part of Greater China, and Simcere will be responsible for the development, registration, and commercialization of paxalisib in that region.
- As with all other territories, Kazia retains all rights to develop and commercialize paxalisib, including in China.
- Simcere is one of China’s fastest-growing pharmaceutical companies and has cancer, autoimmune disease, and neurological disorders its principal strategic areas of focus.
- Paxalisib is currently the target of six additional clinical trials in other brain cancer types outside glioblastoma.
What will KZIA achieve?
The deal entails Kazia Therapeutics (KZIA) receiving an upfront payment of US$ 11 million (AU$ 14.2 million), comprising US$ 7 million in cash and US$ 4 million equity capital at a premium of 20% to recent trading. Further milestones in the US$ 281 million (AU$ 362) range will be paid for indications beyond glioblastoma. A mid-teen royalty will be paid to KZIA on commercial sales by Simcere as well. Paxalisib will be developed further using transaction proceeds.
